PRT3789 Selectively Destroys Cancer's Backup Engine to Kill Resistant Tumors
A first-in-human drug precisely degrades SMARCA2, triggering tumor collapse in lung cancers with SMARCA4 mutations — with early clinical responses confirmed.
Summary
PRT3789 is a targeted protein degrader designed to exploit a genetic vulnerability called synthetic lethality in cancers lacking functional SMARCA4 — a mutation found in roughly 10% of non-small cell lung cancers. When SMARCA4 is lost, tumors become dependent on its near-identical partner, SMARCA2, for survival. PRT3789 selectively destroys SMARCA2 by hijacking a cellular disposal system via the VHL E3 ligase, while sparing SMARCA4. In lab and animal models, this disrupted a key chromatin remodeling complex, reprogrammed gene expression, and caused tumor regression. Crucially, tumors with intact SMARCA4 were largely unaffected, suggesting a favorable safety window. Early clinical trial data show SMARCA2 degradation in patient blood cells and confirmed partial tumor responses in SMARCA4-mutated patients.
Detailed Summary
Roughly 10% of non-small cell lung cancer patients carry mutations that knock out SMARCA4, a protein central to regulating how DNA is packaged and read inside cells. These patients have limited targeted therapy options and poor prognoses, representing a significant unmet medical need. Researchers at Prelude Therapeutics developed PRT3789 specifically to exploit this vulnerability.
SMARCA2 and SMARCA4 are nearly identical paralogs — backup copies of each other — both serving as catalytic engines of the SWI/SNF chromatin remodeling complex. When SMARCA4 is lost to mutation, cancer cells become wholly reliant on SMARCA2 to survive. PRT3789 was engineered as a PROTAC-style degrader that recruits the VHL E3 ubiquitin ligase to tag SMARCA2 for destruction by the cell's own proteasome. Structural analyses revealed that selectivity arises from PRT3789 binding an extended loop region unique to SMARCA2, allowing it to ignore its highly similar paralog.
In SMARCA4-deficient cancer models, SMARCA2 degradation caused the entire SWI/SNF complex to fall apart, disrupting gene expression programs essential for tumor growth. This translated into robust tumor regression in animal models, both alone and in combination with standard chemotherapies or targeted agents. SMARCA4-intact models showed minimal response despite SMARCA2 being degraded, validating the synthetic lethal mechanism and suggesting the drug's toxicity to normal cells may be limited.
In early human clinical trials, PRT3789 successfully reduced SMARCA2 protein levels in patients' peripheral blood immune cells and produced RECIST-confirmed partial tumor responses in SMARCA4-mutated patients — a meaningful early efficacy signal.
Ongoing Phase I/II trials will further define dosing, safety, and efficacy in biomarker-selected patient populations. Key caveats include the early-stage clinical data and the limited patient numbers reported so far.
Key Findings
- PRT3789 selectively degrades SMARCA2 via VHL E3 ligase recruitment, exploiting a loop region unique to SMARCA2.
- SMARCA4-deficient tumors showed robust regression in preclinical models; SMARCA4-intact tumors were largely unaffected.
- SMARCA2 degradation collapsed the entire SWI/SNF chromatin complex, causing broad transcriptional reprogramming in cancer cells.
- Early clinical data confirmed SMARCA2 protein reduction in patient blood cells and RECIST-confirmed partial tumor responses.
- Combination with chemotherapy or targeted therapies enhanced antitumor activity in SMARCA4-deficient preclinical models.
Methodology
Study combined structural biology, cell-based degradation assays, and in vivo tumor models to characterize PRT3789. Mechanism of selectivity was mapped using structure-based analyses of ternary complex formation. Early Phase I/II clinical trial data were included, reporting pharmacodynamic biomarkers and initial tumor response data in SMARCA4-mutated patients.
Study Limitations
Clinical efficacy and safety data are preliminary, drawn from a small number of patients in an ongoing Phase I/II trial. Preclinical findings may not fully translate to clinical outcomes across diverse SMARCA4 mutation types. Long-term durability of responses and resistance mechanisms have not yet been characterized.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: